Fundamental Analysis:
Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company that focuses on the development of a breast cancer immunotherapy treatment to prevent the recurrence of cancer following surgery. This treatment, GP2 , has been undergoing phase two clinical trials for a while, and the data from these trials will be released April...
Fundamental Analysis:
GlycoMimetics, Inc. is a clinical-stage biotechnology company that focuses on developing glycomimetics that inhibit disease-related functions of carbohydrates. They are currently developing a treatment for hormone receptor-positive metastatic breast cancer . The drug, GMI-1359, has undergone phase one safety trials, and the data from these...
